-
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios Athanasios Dimopoulos
Once-weekly carfilzomib at 56 mg/m2 plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT ...
-
Pairing obinutuzumab with venetoclax in relapsed CLL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Kerry A. Rogers, Philip A. Thompson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells via modulation of NF-κB, AP-1, and Akt signaling Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-15 Chie Ishikawa, Naoki Mori
Adult T-cell leukemia (ATL), caused by HTLV-1, is the most lethal hematological malignancy. NEDD8-activating enzyme (NAE) is a component of the NEDD8 conjunction pathway that regulates cullin-RING ...
-
Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-18 Li Li, Wenjing Yang, Yuanyuan Pan, Ruyu Ye, Yu Wang, Sijia Li, Haoyan Jiang, Qi Zhang, Xiaobo Wang, Jinsong Yan
Chidamide (CS055/HBI-8000, tucidinostat) has shown promising effects in the clinical treatment of various hematologic tumors. Diffuse large B-cell lymphoma (DLBCL) has shown highly heterogeneous bi...
-
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-14 Thulasi Raman Ramalingam
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-12 Jinjin Zhu, Mimi Xu, Yuhua Ru, Huanle Gong, Yiyang Ding, Ziling Zhu, Yang Xu, Yi Fan, Xiang Zhang, Yuqing Tu, Aining Sun, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Yue Han, Chengcheng Fu, Suning Chen, Xiao Ma, Feng Chen, Tiemei Song, Depei Wu, Jia Chen
Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suf...
-
The value of bispecific antibodies in relapsed and refractory DLBCL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Katharine Louise Lewis, Chan Yoon Cheah
Diffuse large B-cell lymphoma (DLBCL) may be cured with anti-CD20 based chemoimmunotherapy in the majority of cases, however, relapsed/refractory disease occurs in 30–40% patients, and despite sign...
-
Correction Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-09 Max J. Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D. Miljkovic, Thomas Waldmann, Mark Roschewski
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-08 Brian T. Hill, Yanwen Chen, Deepa Jagadeesh, Robert Dean, Omer Koc, Kirsten Boughan, Brenda Cooper, Brad Pohlman, Paolo Caimi, Mitchell R. Smith
Lenalidomide and rituximab (R2) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteas...
-
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Marie Leroy, Laure Deramoudt, Marine Pinturaud, Julie Demaret, Enagnon Kazali Alidjinou, Morgane Nudel, Doriane Cavalieri, Wadih Abou Chahla, Pascal Odou, Franck Morschhauser, Ibrahim Yakoub-Agha, Nicolas Simon, David Beauvais
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-07 Wisdom Akingbemi, Goldie Kurtz, Nikhil Yegya-Raman, John P. Plastaras, Stephen J. Schuster, Elise A. Chong
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 Jacob Fang, Grace Bosma, Dara Aisner, Christine McMahon, Maria Amaya, Marc Schwartz, Jeff Kaiser, Diana Abbott, Zenggang Pan, Jeffrey Schowinsky, Changlee Pang, Jonathan A. Gutman, Daniel A. Pollyea
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. ...
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-05 Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T. Nawas, Michael W. Drazer, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Anand A. Patel
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-03-03 C. Quivoron, J.-M. Michot, A. Danu, H. Lecourt, V. Saada, K. Saleh, V. Vergé, S. Cotteret, O. A. Bernard, V. Ribrag
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular res...
-
A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-28 Stavroula Asimakopoulou, Panagiotis Malandrakis, Aikaterini Kamiliou, Maria Gavriatopoulou, Konstantina Bafa, Vaios Samaras, Amalia Anastasopoulou, Eleni Variami, Eleftheria Lakiotaki, Penelope Korkolopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Cholongitas
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-29 Adrian Minson, Michael Dickinson
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes – an unusual clinicopathologic presentation with hyperdiploid clone Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-26 Sudipta Naskar, Tanusree Paul, Jayashree D. Kulkarni, K. C. Anand, V. Divya, Harshitha D. Rambhojun
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Mehrnoosh Tashakori, L. Jeffrey Medeiros
Transformation of follicular lymphoma (FL) to a Langerhans cell (LC) neoplasm is extremely uncommon. The shared IGH::BCL2 rearrangement is a robust finding in most transformed tumors underscoring t...
-
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S. Abramson, Robert Redd, Hannah K. Gilman, Terry Ho, Jessica Wu, Julius Heemelaar, Donna Neuberg, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Robb S. Friedman, Ann S. LaCasce, Tomas G. Neilan, Jacob D. Soumerai
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We p...
-
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-23 Naveen Pemmaraju, Yazan F. Madanat, David Rizzieri, Salman Fazal, Raajit Rampal, Gabriel Mannis, Eunice S. Wang, James Foran, Andrew A. Lane
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all pa...
-
Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Chong Wei, Feifei Zhai, Congwei Jia, Wei Zhang, Daobin Zhou, Yan Zhang
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-22 Kevin D. Hofer, Marco M. Bühler, Marco Roncador, Markus Rechsteiner, Ewerton M. Maggio, Joëlle Tchinda, Urs Schanz, Eugenia Haralambieva, Corinne C. Widmer
There is increasing evidence that therapy-related acute lymphoblastic leukemia (trALL) resulting from chemo- and/or radiotherapy represents a distinct entity. However, apart from KMT2A rearrangemen...
-
Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-21 Felix Barajas Ordonez, Denise Wolleschak, Yannic Zeller, Mattes Hinnerichs, Pablo Rodríguez-Feria, Anar Aghayev, Martin Mikusko, Jan Borggrefe, Dimitrios Mougiakakos, Alexey Surov
Studies regarding the influence of body composition parameters as predictors on overall survival (OS) in patients with multiple myeloma (MM) are scarce. OS and progression-free survival (PFS) were ...
-
A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-19 Lindsey Murphy, Bradford Siegele, Billie Carstens, Lisa Hartman, Kelly Faulk
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021 Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-13 Anju Murayama, Hinari Kugo, Sae Kamamoto
Financial interactions between healthcare industry and pediatric hematologist/oncologists (PHOs) could be conflicts of interest. Nevertheless, little is known about financial relationships between ...
-
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where effective treatments options are limited, B-cell maturation antigen and CD3-directed bispecific antibodies offer ...
-
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-10 Simon Østergaard, Lone Schejbel, Marie Fredslund Breinholt, Mette Ølgod Pedersen, Troels Hammer, Lars Munksgaard, Peter Nørgaard, Estrid Høgdall, Lise Mette Rahbek Gjerdrum, Torsten Holm Nielsen
Next-generation sequencing (NGS) affords comprehensive insights into the genomic landscape of lymphomas. We examined the mutational pattern in patients with Waldenström macroglobulinemia (WM) or ly...
-
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-12 Katja Weisel, Meletios A. Dimopoulos, Meral Beksac, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, Istvan Majer, Ian McFadden, Joseph Mikhael
Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance t...
-
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-09 Kenny Tang, Jeffrey H. Lipton
Due to the remarkable success of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), allogeneic stem cell transplantation (alloSCT) is not first-line treatment for delivering durabl...
-
NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-09 Ehsan Tabari, Alexander F. Lovejoy, Hai Lin, Christopher R. Bolen, Seng Lor Saelee, Joshua P. Lefkowitz, David M. Kurtz, Alessia Bottos, Tina G. Nielsen, Joana M. Parreira, Khai T. Luong
Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a next-generation sequencing (NGS)-based method to a...
-
The psychological needs of adolescents and young adults with a diagnosis of myeloproliferative neoplasms: a systematic scoping review of the literature Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-07 Tara Houlihan, Dónal G. Fortune, Clodagh Keohane, Helen L. Richards
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-07 Jean A. Yared, Tsung-Ying Lee, Catherine E. Cooke, Abree Johnson, Amanda Summers, Keri Yang, Sizhu Liu, Boxiong Tang, Eberechukwu Onukwugha
This study characterizes the patterns and timing of CLL treatment and, to our knowledge, is the first to identify social vulnerability factors associated with CLL treatment receipt in the Medicare ...
-
Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-05 Cynthia M. Magro, Taylor Kalomeris, Christina R. Shreve, Julia T. Geyer, Sanjay S. Patel
T cell dyscrasias that demonstrate a proclivity for the subcutaneous fat include atypical lymphocytic lobular panniculitis, lupus profundus, and primary subcutaneous T cell lymphoma, including subc...
-
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-08 Sylvain Garciaz, Guillaume Berton, Marie-Anne Hospital, Arnaud Guille, José Adélaïde, Colombe Saillard, Yosr Hicheri, Marie-Joëlle Mozziconacci, Estelle Duprez, Christian Récher, Anne-Sophie Alary, Daniel Birnbaum, Norbert Vey
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Hematopoietic cell transplantation (HCT) in MDS patients of older age Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-05 Christian Niederwieser, Nicolaus Kröger
Hematopoietic cell transplantation (HCT) has evolved to an essential treatment in younger and more recently in elderly patients with myelodysplastic syndrome (MDS), the age group with the highest i...
-
Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells Leuk. Lymphoma (IF 2.6) Pub Date : 2024-02-01 Seiichi Okabe, Mitsuru Moriyama, Akihiko Gotoh
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL) Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-31 Amen Allah Nasr, Xavier Fund, Sylvain Barreau, Christophe Desterke, Claire Borie, Noufissa Oudrhiri, Jamila Faivre, A. Bennaceur-Griscelli, A. G. Turhan
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-31 Matthew M. Lei, Mark N. Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Ford, Ronald A. Nemec, Jeremy S. Abramson, Jacob D. Soumerai
Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-w...
-
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Sumedha Arya, Lee Mozessohn, Inna Gong, Neil Faught, Ning Liu, Simron Singh, Kelvin Chan, Matthew C. Cheung
The aim of this study was to describe the impact of marginalization on DLBCL overall survival (OS) within the Canadian setting. We conducted a population-based retrospective cohort study of adult p...
-
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Anath C. Lionel, Ashwath Gurumurthi, Ahmed Fetooh, Rami Eldaya, Sairah Ahmed, Swaminathan P. Iyer, Loretta J. Nastoupil, Jason Westin, Ranjit Nair, Luis Fayad, Luis Malpica, Sudhakar Tummala, Christopher Flowers, Sattva S. Neelapu, Michael L. Wang, Preetesh Jain
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Ivan Krecak, Danijela Lekovic, Dragana Grohovac, Anica Sabljic, Hrvoje Holik, Ivan Zekanovic, Martina Moric Peric, Davor Galusic, Vlatka Perisa, Filip Krecak, Marko Skelin, Marko Lucijanic
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-22 Tamar Tadmor, Ilana Levy Yurkovski
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
-
Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Serena Tharakan, John Mascarenhas, Douglas Tremblay
Myeloproliferative neoplasms (MPNs) that lack the classical “driver mutations,” termed triple negative MPNs, remain a poorly understood entity. Despite considerable progress toward understanding MP...
-
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Craig W. Freyer, Alison Carulli, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Mary Ellen Martin, Selina M. Luger, David L. Porter, Edward A. Stadtmauer, Alison W. Loren
Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilatera...
-
Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Clare Grieve, Ashlee Joseph, Pamela Drullinsky, Andrew D. Zelenetz, Paul Hamlin, Anita Kumar
This dose-finding study evaluated safety of venetoclax plus Bendamustine-Rituximab-Ibrutinib in relapsed/refractory MCL. Six 28-day cycles were administered in a 3 + 3 dose-escalation design. Dose ...
-
BCMA CAR-T cells in multiple myeloma–ready for take-off? Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Lukas Scheller, Erius Tebuka, Peter Fabian Rambau, Hermann Einsele, Michael Hudecek, Sabrina Rebecca Prommersberger, Sophia Danhof
Although the approval of new drugs has improved the clinical outcome of multiple myeloma (MM), it was widely regarded as incurable over the past decades. However, recent advancements in groundbreak...
-
Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Emma Verstraete, Cédric Baumann, Hélène Rousseau, Arnaud Campidelli, Marie-Thérèse Rubio, Maud D’Aveni
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Shaimaa El-Ashwah, Jon Salmanton-García, Yavuz M. Bilgin, Federico Itri, Pavel Žák, Barbora Weinbergerová, Luisa Verga, Ali S. Omrani, Maria Gomes da Silva, Tomáš Szotkowski, Monia Marchetti, Caterina Buquicchio, Marcio Nucci, Martin Schönlein, Francesca Farina, Caroline Besson, Lucia Prezioso, Summiya Nizamuddin, Julio Dávila-Valls, Sonia Martín-Pérez, Valentina Bonuomo, Jaap Van Doesum, Maria Chiara
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from...
-
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Ludovic Fouillet, Elisabeth Daguenet, Emmanuelle Tavernier, Hervé Ghesquières, Emmanuel Bachy, Pierre Sesques, Olivier Tournilhac, Jacques-Olivier Bay, Anne-Sophie Michallet, Manon Sapet, Emilie Chalayer, Denis Guyotat, Fabien Tinquaut, Jérôme Cornillon
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Ruchi Patel, Arushi Singh, Zhiying Meng, Abigail S. Baldridge, Daniel Addison, Nausheen Akhter
For ibrutinib-related atrial fibrillation (IRAF), guidelines for anticoagulation do not exist. We sought to describe stroke, bleeding, and anticoagulation rates among patients with IRAF. We perform...
-
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Jiawang Ou, Xiuli Xu, Shiyu Deng, Haimei Liang, Zihong Cai, Jia Li, Zicong Huang, Bingqing Tang, Zhixiang Wang, Ya Zhou, Xiaoli Liu, Qifa Liu, Hongsheng Zhou
The prognostic impact of TP53 mutations (TP53mut) in adult acute lymphoblastic leukemia (ALL) remains debatable. Herein, we determined the clinical significance of TP53mut in 283 adult ALL patients...
-
Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Christy J. Khouderchah, Lydia L. Benitez, Bernard L. Marini, Martina Fraga, Kristen Pettit, Patrick W. Burke, Dale L. Bixby, Anthony J. Perissinotti
Venetoclax with hypomethylating agents (HMAs) is an important treatment for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. However, there is limited data on ...
-
The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells* Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Narjis Fatima, O. Giles Best, Larissa Belov, Richard I. Christopherson
In humans, AMPylation of cellular proteins is carried out by Huntingtin yeast-interacting protein E (HYPE), activated under conditions of endoplasmic reticulum stress, such as in cancer cells. Extr...
-
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Anna Puła, Tadeusz Robak, Izabela Dróżdż, Konrad Stawiski, Aleksander Rycerz, Małgorzata Misiewicz, Paweł Robak
Despite advances in multiple myeloma (MM) treatment, drug resistance remains a clinical challenge. We aimed to develop a prognostic model for bortezomib resistance based on miRNA expression profili...
-
Primary cutaneous anaplastic large cell lymphoma with DUSP22-rearrangement presenting as a mimicker of mycosis fungoides: a case report and review of the literature Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 João M. Pacheco, Stephan Forchhammer, Franziska Otto, Falko Fend, Leonie Frauenfeld
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Oktawia Sośnia, Katarzyna Pruszczyk, Michał Danecki, Ewa Wąsik-Szczepanek, Jagoda Tryc-Szponder, Elżbieta Iskierka-Jażdżewska, Alan Majeranowski, Helena Krzemień, Łukasz Bołkun, Ewa Paszkiewicz-Kozik, Joanna Drozd-Sokołowska, Jacek Kwiatkowski, Dominika Wiśniewska-Organek, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz, Bożena Budziszewska, Krzysztof Jamroziak, Iwona Hus, Ewa Lech-Marańda, Bartosz
Richter transformation (RT) is defined as developing an aggressive lymphoma in 2–10% of patients suffering from chronic lymphocytic leukemia (CLL). So far, no complex analysis of RT demographics an...
-
Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Amélie Trinquand, David R. Betts, Shauna Harte, Aoife Sills, Sean Rooney, Neil Barrett, Lorna Storey, Andrea Malone, Aengus O’Marcaigh, Owen P. Smith
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Hidehiro Itonaga, Takeharu Kato, Yasushi Sawayama, Shinichi Katsuoka, Takafumi Furumoto, Nariyoshi Matsumoto, Daisuke Sasaki, Yuichi Yamada, Miki Hashimoto, Machiko Fujioka, Hikaru Sakamoto, Hiroo Hasegawa, Yoshitaka Imaizumi, Kazuhiro Nagai, Katsunori Yanagihara, Yasushi Miyazaki
Published in Leukemia & Lymphoma (Vol. 65, No. 2, 2024)
-
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis Leuk. Lymphoma (IF 2.6) Pub Date : 2024-01-24 Neslihan Meriç, Esra Albayrak, Zafer Gülbaş, Fatih Kocabaş
Leukemia stem cells (LSCs) exhibit self-renewal, resistance to standard treatments, and involvement in leukemia relapse. Higher Myeloid Ecotropic Integration Site-1 (MEIS1) expression in leukemic b...